Verrica Pharmaceuticals Inc (FRA:1NE0)

Q1 2026 Verrica Pharmaceuticals Inc Earnings Call Transcript

May 12, 2026 / 08:30 PM GMT

Release Date Price: €6.14 (-7.67%)

Transcript 10-Q8-K

Key Points

Positve

Verrica Pharmaceuticals Inc (VRCA) reported a 25.4% increase in U.S. Ycamp product revenue compared to the first quarter of 2025.
The company achieved a significant milestone with the launch of Wycanth in Japan by Torii Pharmaceuticals, marking the beginning of global expansion efforts.
Verrica Pharmaceuticals Inc (VRCA) has made substantial progress in its Phase III program for the treatment of common warts, achieving over 50% of targeted enrollment.
The company reported a strong gross product margin of 87.3% for the first quarter of 2026.
Verrica Pharmaceuticals Inc (VRCA) has retained 100% global commercial rights to its products outside of Japan, presenting robust partnership opportunities.

Negative

Verrica Pharmaceuticals Inc (VRCA) reported a GAAP net loss of $9.7 million for the first quarter of 2026, consistent with the previous year.
Research and development expenses increased by $1.5 million compared to the first quarter of 2025, driven by spending on the Common Warts Program.
Selling, general, and administrative expenses rose by $1.3 million due to increased commercial spending.
The company is still in the early stages of its Europe planning and strategy, with ongoing activities to understand pricing and reimbursement.
Verrica Pharmaceuticals Inc (VRCA) has not yet provided guidance for the full year, indicating uncertainty in future financial performance.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

VRCA.OQ - Verrica Pharmaceuticals Inc
Q1 2026 Verrica Pharmaceuticals Inc Earnings Call
May 12, 2026 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Please stand by. Your meeting is about to begin.

Good day, ladies and gentlemen, and welcome to the Verica Pharmaceuticals first quarter 2026 earnings conference call.

At this time, all participants are in a listen-only mode.

After the speaker's remarks, there will be a question-and-answer session.

As a reminder, this conference is being recorded.

I will now turn the call over to our host, Kevin Gardner of LifeSci Advisors. You may begin your conference.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you,

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.